Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
about
New targets for therapy in breast cancer: farnesyltransferase inhibitors.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Therapeutic intervention based on protein prenylation and associated modificationsAdaptive dose-finding studies: a review of model-guided phase I clinical trials.RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.Farnesyltransferase inhibitors reverse taxane resistanceThe synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.Novel targeted agents in the treatment of lung cancer.Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.Lonafarnib in cancer therapy.Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomasProtein kinases as targets for cancer treatment.Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy.Lonafarnib for cancer and progeria.The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.Computational studies of the farnesyltransferase ternary complex part II: the conformational activation of farnesyldiphosphate.Finding a needle in the haystack: computational modeling of Mg2+ binding in the active site of protein farnesyltransferase.Computational studies of the farnesyltransferase ternary complex part I: substrate binding.On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors
P2860
Q24796277-B50BBD6B-2FD8-485B-8B58-F59E2368A0CDQ33914284-10D82B9E-0703-4402-991A-D230CBE0F408Q33943379-8C3E28BA-E822-4E75-B2D3-F3BCA90864CAQ34001009-93FAE087-189F-4C64-8155-D2A4BB068EE7Q34048144-EE569E0F-8771-443E-B232-5A6F19AAF207Q35091519-70A41FA3-1BDF-448E-9369-1F8E83032A86Q35774556-F840E387-F5FE-4633-9A40-BF8783646357Q35774565-E83EC652-82CA-46FD-8315-A143C324EDCDQ35790783-8F0F7CD2-AFCE-4A85-B9B4-1CB45E635883Q35872060-AAB5277E-986F-4BB4-B196-23A338C0FC52Q36491847-067C2601-936E-4B22-9ED2-B85F377B54FCQ36693797-7DA0EE4E-3FF8-4A08-8115-88B8B440CD60Q36918131-D8769D44-2030-4D2A-9E7A-AD3D090E8ACDQ36946766-8A8BE2BE-7948-4D1D-8A8C-2A95A1448B6BQ37039386-397E4ADD-9DC4-4188-9006-33EC76180AF5Q38012480-FCCBA1AB-1C43-48DE-919E-0173C176BAC4Q40134426-DBA5A60B-6CED-4B29-8B93-4B5263C67311Q42138995-93A3EDD4-9C5F-4E01-8D3B-F44C07AE4731Q42592350-8EB5F8D0-668E-4D3C-9C05-E570F4E0A760Q42949282-30817D07-ED84-4B8B-9A06-2FAE5BD146FBQ46544698-86D2341E-EBB2-4E41-A8FF-5548AAF08CD1Q49080340-0D4A9904-2842-4DFD-BF42-4EBC18C9F0F1Q49787333-E0134DB9-8817-4972-BAF1-49F289C1DC10Q54478541-6101C365-D0F4-4EC7-BF15-8CEE28C83971Q58289073-0E21B0FD-EB68-4D44-BF49-9ED41FF70DA1
P2860
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Phase I study of the farnesylt ...... th paclitaxel in solid tumors.
@en
type
label
Phase I study of the farnesylt ...... th paclitaxel in solid tumors.
@en
prefLabel
Phase I study of the farnesylt ...... th paclitaxel in solid tumors.
@en
P2093
P50
P1476
Phase I study of the farnesylt ...... th paclitaxel in solid tumors.
@en
P2093
Bonnie S Glisson
Charles Lu
Craig Tendler
Dong M Shin
Edward S Kim
Elizabeth Thompson
Fadlo R Khuri
Merrill S Kies
Michael L Meyers
Paul Kirschmeier
P304
P356
10.1158/1078-0432.CCR-03-0412
P407
P577
2004-05-01T00:00:00Z